$OXMNeutralMed

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports First Quarter Results

Oxford Industries (NYSE:OXM) reported first-quarter fiscal 2026 results for the period ended May 2, 2026. Net sales were $391.4 million vs. $392.9 million a year earlier. GAAP EPS fell to $1.00 from $1.70; adjusted EPS was $1.39 vs. $1.82. The company cited tariff costs and lower gross margin. It narrowed full-year sales guidance to $1.475–$1.505 billion and raised adjusted EPS to $2.30–$2.70.

9/10
8/10
Med
Neutral
after-hours/next-session positioning following Q1 print and guidance update
guidance mix (sales cautious, EPS low-end raised) likely aligns with a cautious but not bearish sentiment

Tariff-driven margin/EPS pressure in Q1 is being partially offset by sourcing/pricing actions and lower tariff rates expected to persist, leading to a mixed guidance update.

Oxford Industries reported Q1 FY2026 results and narrowed full-year sales guidance while raising the low end of EPS guidance amid tariff-cost pressure.

Near-term bias likely mixed: downside risk from weaker GAAP profitability and softer consumer backdrop, offset by raised low-end EPS and expectation of continued lower tariffs.

Background

Oxford Industries (Tommy Bahama, Lilly Pulitzer, Johnny Was) reported Q1 FY2026 results and provided updated full-year guidance amid tariff costs and weaker consumer sentiment.

Why it matters

Q1 showed flat-to-down revenue with a sharp GAAP EPS decline and lower gross margin, driven by incremental tariff costs and higher LIFO charges. Management narrowed sales guidance (lowering the top end) but raised the low end of adjusted EPS, citing continued lower tariff rates plus disciplined expense/inventory management.

Market relevance

Traders can reprice OXM based on the guidance mix: cautious sales outlook versus improved EPS floor supported by expected lower tariff rates and cost discipline.

Market effects

Signals apparel/consumer discretionary exposure to tariffs and consumer sentiment; margin sensitivity to tariff and LIFO accounting remains a key swing factor.

Limited direct regional read-through beyond US consumer and logistics/distribution execution (Lyons, GA).

Tariff cost language implies ongoing cross-border input cost risk, relevant to broader import-dependent retail supply chains.

Alternative perspectives

The raised EPS low-end could indicate management has more control over costs/mix than the headline sales softness suggests, potentially limiting downside versus the market’s tariff fears.

Royalties declined due to licensing partners’ tariff-hit sales; if partner demand stabilizes, royalty income and brand momentum (Tommy Bahama comps) could improve faster than implied by consolidated sales.

Key entities

  • Oxford Industries, Inc.

    Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was; released Q1 FY2026 results and updated FY2026 guidance.

  • Tom Chubb

    Chairman and CEO who attributed performance to brand comps, tariff costs, and corrective actions at Lilly Pulitzer.

  • Lyons, Georgia distribution center

    Transition costs and capex referenced as part of SG&A and investment activity.

Related articles

$OXMMedAI 8/10

Oxford (OXM) Q1 2026 Earnings Transcript

Oxford Industries (OXM) reported Q1 2026 net sales of $391M, slightly below $393M a year earlier but within guidance (midpoint $385M–$395M). Comparable sales fell 2% (retail and e-commerce down 2%; wholesale down 5%). Adjusted gross margin fell 90 bps to 63.4% due to $11M incremental tariff costs; adjusted EPS was $1.39. Full-year sales guidance raised to $1.48B–$1.505B and adjusted EPS narrowed to $2.30–$2.70.

$OXMMed

OXFORD INDUSTRIES INC (OXM): Results of Operations and Financial Condition

OXFORD INDUSTRIES INC (OXM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 oxm-5022026xexx991.htm EX-99.1 Document EXHIBIT 99.1 Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports First Quarter Results ATLANTA, June 10, 2026 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its first

$AZNHighAI 8/10

AstraZeneca Plunges After New Heart Disease Drug Fails Trial

AstraZeneca said its heart disease drug Wainua failed to beat placebo in a clinical trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to AstraZeneca and Ionis Pharmaceuticals. AstraZeneca shares fell up to 10.6% in London and 5.7% on the NYSE. Rival ATTR-CM drug makers Pfizer, BridgeBio, and Alnylam initially moved higher or lower.

$WDFCMedAI 8/10

WD-40 Q3 Earnings Call Highlights

WD-40 Company (NASDAQ:WDFC) reported Q3 gross margin of 56.6% and non-GAAP net income of $31.5 million, with non-GAAP EPS of $2.33. EMEA sales rose 17% to $66.6 million and Asia-Pacific sales rose 24% to $27.3 million. FY2026 constant-currency net sales guidance is $652 million to $667 million. The board authorized a $100 million share repurchase program.